Cue Biopharma, Inc. Annual Report - Investor Summary

Discover how Cue Biopharma, Inc. navigated 2023, advancing its innovative immunotherapy pipeline and securing a major partnership. This summary distills the company's recent 10-K filing, offering retail investors a clear and engaging look at its operations, financial health, and strategic direction for the fiscal year ended December 31, 2023.

Business Overview

Cue Biopharma, Inc. (trading as CUE on the Nasdaq Capital Market) is a clinical-stage biopharmaceutical company dedicated to developing new immunotherapies for cancer and autoimmune diseases. The company's unique Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform precisely guides the immune system by delivering specific signals directly to the T cells involved in disease.

In 2023, Cue Biopharma significantly advanced its drug development pipeline. Key programs include:

• CUE-101 Series: These Immuno-STATs are designed to activate specific T cells that target tumors in various cancers. CUE-101, the company's lead drug candidate, is currently in Phase 1 clinical trials for HPV16+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
• CUE-401: This Immuno-STAT aims to selectively increase regulatory T cells (Tregs) to treat autoimmune diseases. The company submitted an Investigational New Drug (IND) application for CUE-401 in late 2023, a critical step allowing clinical trials to begin, which they anticipate starting in 2024.
• CUE-500 Series: This early-stage research program focuses on developing Immuno-STATs for various autoimmune conditions.

A major strategic highlight in 2023 was the licensing of CUE-501, an early-stage autoimmune candidate from the CUE-500 series, to Boehringer Ingelheim International GmbH. This collaboration, announced in Q3 2023, brought Cue Biopharma an upfront payment of $15 million. The agreement also includes potential milestone payments exceeding $400 million for development and commercial achievements, plus tiered royalties on future sales. This deal not only validates Cue Biopharma's platform technology but also provides capital that doesn't dilute existing shareholder ownership, enabling the company to focus its internal resources on other key pipeline assets.

Financial Performance

For the fiscal year ended December 31, 2023, Cue Biopharma reported the following:

• Total Revenue: $18.5 million, a substantial increase from $3.2 million in 2022. This growth primarily stemmed from the upfront payment received through the Boehringer Ingelheim collaboration, whereas 2022 revenue mainly came from research grants.
• Research and Development (R&D) Expenses: $58.3 million, a slight rise from $55.9 million in 2022. This reflects the company's continued investment in its clinical and early-stage research programs.
• General and Administrative (G&A) Expenses: $18.7 million, compared to $17.5 million in 2022.
• Net Loss: $59.2 million, or ($1.05) per share, a reduction from a net loss of $69.8 million, or ($1.30) per share, in 2022. Collaboration revenue primarily drove this improved net loss.

As of December 31, 2023, Cue Biopharma's market capitalization stood at approximately $52.0 million, with a share price of $0.68. Like many biopharmaceutical companies in the clinical development stage, Cue Biopharma is not yet profitable and continues to invest significantly in R&D to advance its drug candidates.

Risk Factors

Investing in Cue Biopharma involves substantial risks, common in the biopharmaceutical industry. These include:

• Clinical Trial Failure: Most drug candidates do not succeed in clinical development. Negative or unclear results from CUE-101, CUE-401, or other programs would severely impact the company. The success of their drug candidates remains uncertain and depends on positive outcomes from current and future preclinical (laboratory and animal studies) and clinical (human) trials.
• Regulatory Approval Uncertainty: Obtaining approvals from regulatory bodies like the FDA is a long, complex, and unpredictable process. Delays or rejections are common and could prevent commercialization. Increasing scrutiny from regulators regarding drug safety, effectiveness, and pricing can also affect development timelines and market access.
• Funding and Dilution Risk: The company will need significant additional capital to fund its operations and advance its pipeline. Future equity financings, where the company sells more shares, could substantially dilute the ownership stake of current shareholders. The company spends cash quickly (known as "cash burn"), and its ability to continue operations heavily relies on securing more funding.
• Competition: The immunology and oncology markets are highly competitive. Many large pharmaceutical companies and well-funded biotech firms are developing similar or potentially superior therapies.
• Intellectual Property (IP) Protection: The company's success depends on its ability to obtain, maintain, and enforce patents and other intellectual property rights. Challenges to their IP could weaken their competitive position.
• Reliance on Third Parties: Cue Biopharma depends on contract research organizations (CROs) to conduct clinical trials and contract manufacturing organizations (CMOs) for drug production. This reliance introduces risks related to quality, timelines, and costs.
• Product Commercialization: Even if a drug receives approval, there is no guarantee of market acceptance, favorable pricing, or successful sales.
• "Going Concern" Risk: If the company cannot secure additional funding, significant doubt exists about its ability to continue operating as a "going concern" (meaning it can meet its obligations) beyond its current cash reserves (or "cash runway").
• Economic Headwinds: Broader economic factors, such as inflation, interest rates, and global supply chain disruptions, can increase operational costs and make it harder to access capital.
• Evolving Reimbursement Landscape: Changes in healthcare policies and how drugs are reimbursed can affect the financial viability of approved medicines.

Management Discussion (MD&A Highlights)

The Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) provides a detailed narrative of Cue Biopharma's performance and financial position. In 2023, the $15 million upfront payment from the Boehringer Ingelheim collaboration significantly boosted the company's financial results, increasing revenue and reducing the net loss compared to the previous year, even with continued investment in research and development.

Results of Operations: As outlined in the Financial Performance section, R&D expenses saw a slight increase to $58.3 million. This reflects ongoing pipeline advancement, particularly with the CUE-101 series and the IND filing for CUE-401. General and administrative expenses also rose modestly. The collaboration revenue played a key role in moderating the net loss.

Liquidity and Capital Resources: As discussed in the Financial Health section, the company concluded 2023 with $38.7 million in cash and cash equivalents. This amount, combined with the upfront payment from Boehringer Ingelheim, is expected to fund operations and capital expenditures into the third quarter of 2024. Cue Biopharma carries no significant long-term debt but faces a critical need for additional funding to sustain operations beyond this period, highlighting a significant liquidity risk.

Key Developments and Strategic Focus: Major achievements included the strategic partnership with Boehringer Ingelheim, which validated the Immuno-STAT™ platform and provided non-dilutive capital. The IND filing for CUE-401 marked a crucial step in expanding into autoimmune diseases. The company refined its pipeline strategy to optimize resource allocation, concentrating on its lead oncology candidate (CUE-101) and the advancing autoimmune program (CUE-401). The company reported no major changes to its executive leadership team in 2023.

Known Trends and Uncertainties: The biopharmaceutical industry constantly evolves with rapid scientific advancements, intense competition, and a complex regulatory environment. Cue Biopharma operates within a "precision medicine" framework, aligning with growing industry trends toward targeted therapies. However, the company faces uncertainties related to regulatory scrutiny, broader economic challenges affecting operational costs and capital access, and changes in the reimbursement landscape. All these factors could impact development timelines and commercial viability. The company continuously monitors these external factors.

Financial Health

As of December 31, 2023, Cue Biopharma reported $38.7 million in cash and cash equivalents, down from $55.1 million at the end of 2022. The company estimates that its current cash and cash equivalents, along with the upfront payment from Boehringer Ingelheim, will cover its operating expenses and capital needs into the third quarter of 2024.

Cue Biopharma has no significant long-term debt. However, given its current rate of spending (approximately $15-20 million per quarter), the company will require substantial additional funding to continue its research and development activities beyond Q3 2024. This situation underscores a critical liquidity risk and the potential need for future equity offerings or new partnerships.

Future Outlook

Cue Biopharma's future success depends on the effective execution of its clinical development plans and its ability to secure necessary funding. The company reaffirmed its strategic focus on advancing its Immuno-STAT™ platform in both oncology and autoimmune diseases. The decision to license CUE-501 to Boehringer Ingelheim was a deliberate move to reduce the financial risk of that program, generate capital without issuing new shares, and allow the company to concentrate its internal resources on its lead oncology candidate (CUE-101) and the rapidly progressing autoimmune program (CUE-401).

Key upcoming milestones include:

• Starting Phase 1 clinical trials for CUE-401 in autoimmune diseases in 2024.
• Continuing patient enrollment and releasing data from the CUE-101 Phase 1 clinical trial.
• Advancing early-stage research programs within the CUE-500 series and other oncology candidates.
• Potentially forming additional strategic collaborations or partnerships to further validate their platform and provide funding.

The company's ability to achieve these milestones and ultimately bring new medicines to market will be crucial for long-term value creation. However, this heavily relies on its success in raising additional capital and achieving positive clinical trial outcomes.

Competitive Position

Cue Biopharma distinguishes itself through its proprietary Immuno-STAT™ platform, which aims for precise and selective modulation of T cells. This targeted approach seeks to overcome the limitations of broader immunotherapies by minimizing unwanted side effects and enhancing effectiveness. The company's intellectual property portfolio, including patents covering its Immuno-STAT™ molecules and their uses, is vital to its competitive advantage. The Boehringer Ingelheim partnership further validates the potential of their technology. However, Cue Biopharma faces intense competition from companies developing other forms of immunotherapy, such as checkpoint inhibitors, CAR-T therapies, and other T-cell modulators, from major players like Merck, Bristol Myers Squibb, Novartis, and Regeneron.